Fosmidomycin Decreases Membrane Hopanoids and Potentiates the Effects of Colistin on Burkholderia multivorans Clinical Isolates by Malott, Rebecca J. et al.
  Published Ahead of Print 23 June 2014. 
10.1128/AAC.02705-14. 
2014, 58(9):5211. DOI:Antimicrob. Agents Chemother. 
Newman and David P. Speert
Hird, Nathan F. Dalleska, James E. A. Zlosnik, Dianne K. 
Rebecca J. Malott, Chia-Hung Wu, Tracy D. Lee, Trevor J.
 
Clinical Isolates
Colistin on Burkholderia multivorans
Hopanoids and Potentiates the Effects of 
Fosmidomycin Decreases Membrane
http://aac.asm.org/content/58/9/5211
Updated information and services can be found at: 
These include:
REFERENCES
http://aac.asm.org/content/58/9/5211#ref-list-1at: 
This article cites 41 articles, 18 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 O
ctober 2, 2014 by CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 O
ctober 2, 2014 by CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y
http://aac.asm
.org/
D
ow
nloaded from
 
Fosmidomycin Decreases Membrane Hopanoids and Potentiates the
Effects of Colistin on Burkholderia multivorans Clinical Isolates
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Centre for Understanding and Preventing Infection in Children, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canadaa; Division of
Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USAb; Environmental Analysis Center, California Institute of Technology,
Pasadena, California, USAc; Howard Hughes Medical Institute, Pasadena, California, USAd; Division of Geological and Planetary Sciences, California Institute of Technology,
Pasadena, California, USAe
Burkholderia cepacia complex (Bcc) pulmonary infections in people living with cystic fibrosis (CF) are difficult to treat because
of the extreme intrinsic resistance of most isolates to a broad range of antimicrobials. Fosmidomycin is an antibacterial and an-
tiparasitic agent that disrupts the isoprenoid biosynthesis pathway, a precursor to hopanoid biosynthesis. Hopanoids are in-
volved in membrane stability and contribute to polymyxin resistance in Bcc bacteria. CheckerboardMIC assays determined that
although isolates of the Bcc species B.multivoranswere highly resistant to treatment with fosmidomycin or colistin (polymyxin
E), antimicrobial synergy was observed in certain isolates when the antimicrobials were used in combination. Treatment with
fosmidomycin decreased theMIC of colistin for isolates as much as 64-fold to as low as 8g/ml, a concentration achievable with
colistin inhalation therapy. A liquid chromatography-tandemmass spectrometry technique was developed for the accurate
quantitative determination of underivatized hopanoids in total lipid extracts, and bacteriohopanetetrol cyclitol ether (BHT-CE)
was found to be the dominant hopanoid made by B.multivorans. The amount of BHT-CEmade was significantly reduced upon
fosmidomycin treatment of the bacteria. Uptake assays with 1-N-phenylnaphthylamine were used to determine that dual treat-
ment with fosmidomycin and colistin increases membrane permeability, while binding assays with boron-dipyrromethene-con-
jugated polymyxin B illustrated that the addition of fosmidomycin had no impact on polymyxin binding. This work indicates
that pharmacological suppression of membrane hopanoids with fosmidomycin treatment can increase the susceptibility of cer-
tain clinical B.multivorans isolates to colistin, an agent currently in use to treat pulmonary infections in CF patients.
Lung damage due to recurrent and chronic pulmonary infec-tions is the major cause of morbidity and mortality in people
living with cystic fibrosis (CF). The Burkholderia cepacia complex
(Bcc) is composed of at least 18 closely related Gram-negative
species with remarkable metabolic versatility (1). This group of
bacteria emerged in the 1980s as opportunistic pulmonary patho-
gens of particular importance to patients with CF (2–4). Bcc bac-
teria are ominous CF pathogens because of their potential to cause
rapid clinical deterioration and death (3). The major challenge to
clinical therapy of Bcc pulmonary infections is their innate resis-
tance to a broad range of antimicrobials, including polycationic
agents that are typically used to treat other CF pulmonary patho-
gens (5). Although Burkholderia cenocepacia has widely been con-
sidered the most prevalent and virulent Bcc species in CF infec-
tions, the proportion ofB.multivorans infections is increasing (6),
with its incidence in CF patients now exceeding that of B. cenoce-
pacia in the United States and Canada (7, 8). Epidemic outbreaks
of B. multivorans causing severe morbidity and mortality in CF
patients were described in the United Kingdom (9) and France
(10). B.multivorans was selected as the model Bcc species for this
study.
To combat increasing antimicrobial resistance, physicians are
increasingly turning to polymyxins, especially inhaled colistin
(polymyxin E), for therapy of the major CF respiratory pathogen
Pseudomonas aeruginosa (11). Polymyxins are rapid-acting bacte-
ricidal cationic peptides with detergent-like properties. These
agents accumulate in the bacterial membrane and affect selective
permeability. Polymyxin therapy is not considered an option for
CF patients with Bcc infections because of the high constitutive
polymyxin resistance of these bacteria. The intrinsic resistance of
Bcc bacteria to polymyxins is multifaceted (12) but is due primar-
ily to unique features of the cell membrane (12, 13). Polymyxin B
binds poorly to its lipopolysaccharide (LPS) target sites on intact
Bcc cells (14). There is a constitutive presence of 4-amino-4-de-
oxy-L-arabinose linked to the lipid A phosphate groups in the LPS
of Bcc bacteria, eliminating the negative charge required for poly-
myxin binding (15). The composition of the LPS core oligosac-
charide is also responsible in part for the resistance of B. cenoce-
pacia to polymyxin B (16, 17).
Beyond these issues of binding, the contribution of membrane
hopanoids to polymyxin resistance in the Bcc has been revealed
recently (18–20). Hopanoids are pentacyclic triterpenoid lipids
that are analogues of cholesterol in prokaryotic membranes. They
are involved in membrane stability and barrier function (21) and
contribute to the maintenance of membrane fluidity and perme-
ability (21, 22). Not all bacteria produce hopanoids, and few bac-
teria associated with human infections possess the genetic ma-
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chinery necessary for their biosynthesis (18). Yet the key hopanoid
biosynthesis gene shc, which encodes the squalene-hopene cyclase,
is distributed throughout the sequenced Bcc species (18). Ho-
panoids have been isolated from a variety of Burkholderia spp. but
not from the closely related and typically polymyxin B-sensitive
Pseudomonas spp. and Ralstonia spp. (23).
B. cenocepacia hopanoid biosynthesis mutants are more sus-
ceptible than their wild-type parents to antimicrobials, including
polymyxin B (20), as well asmembrane-disrupting agents, includ-
ing chlorhexidine (19) and sodium dodecyl sulfate (SDS) (20). In
B. multivorans, hopanoid biosynthesis specifically contributes to
resistance to polymyxins (polymyxin B and colistin) (18). The
hopanoid biosynthesis mutants exhibited an up-to-8-fold in-
crease in polymyxin B susceptibility and a 16-fold increase in
colistin susceptibility compared to the parentB.multivorans strain
(18). This increased susceptibility to polymyxins was demon-
strated to be due to altered membrane permeability in the ho-
panoid biosynthesis mutants and not to an alteration of poly-
myxin binding capacity (18).
Fosmidomycin is a phosphonic acid derivative with antibac-
terial and antiparasitic activities. This agent acts exclusively on
enzymes of the nonmevalonate pathway of isoprenoid biosyn-
thesis by directly inhibiting 1-deoxy-D-xylulose 5-phosphate
reductoisomerase and indirectly inhibiting a downstream en-
zyme, methylerythritol phosphate cytidyltransferase (IspD)
(24). Bacteria synthesize isoprenoids to serve as the prenyl
chains of the ubiquinones and menaquinones of the electron
transport chains, as carbohydrate carriers for the biosynthesis
of peptidoglycan, or as precursors to hopanoid biosynthesis
(25). Bcc bacteria are highly resistant to fosmidomycin because
of insufficient uptake of the agent into the bacteria and the
presence of an efflux pump that efficiently transports any in-
ternalized fosmidomycin out of the cell (26).
Although Bcc species are highly resistant to monotherapy with
either fosmidomycin or polymyxins, here we sought to test the
hypothesis that inhibition of isoprenoid biosynthesis by fosmido-
mycin would reduce the concentration of hopanoids in the bacte-
rial membrane and potentiate the inhibitory effects of polymyxins
on B.multivorans growth. This work serves as proof of the princi-
ple that suppressing the concentration of hopanoids in the bacte-
rial membrane can increase the susceptibility of particular clinical
B.multivorans strains to antimicrobials that are currently used to
treat P. aeruginosa infections, thereby providing physicians with a
new therapeutic option to consider for B. multivorans.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. B. multivorans
ATCC 17616 and P. aeruginosa ATCC 27853 were obtained from the
American Type Culture Collection (ATCC; Manassas, VA). The B. mul-
tivorans hopanoid biosynthesis mutants 26D7 (Bmul_2133::Tn5) and
RMI17 (Bmul_2134) were constructed for our previous study (18). B.
multivorans clinical isolates are part of the Canadian Bcc Research and
Referral Repository (CBCCRRR), housed in D. P. Speert’s laboratory
(27). B. cenocepacia K56-2 (28) was a gift from P. A. Sokol of the Univer-
sity of Calgary. All strains were stored at70°C in cation-adjusted Muel-
ler-Hinton II (MH) broth with 8.0% (vol/vol) dimethyl sulfoxide. For
routine bacterial growth, Luria-Bertani or MH broth was used. Unless
otherwise stated, bacteria were incubated at 37°C and liquid cultures were
grown with aeration. Bacteriological medium components were pur-
chased from Becton, Dickinson and Company (Sparks, MD), and all
chemicals and antibiotics were from Sigma-Aldrich Canada Ltd.
(Oakville, ON, Canada) unless otherwise stated. Fosmidomycin was pur-
chased from Life Technologies (Burlington, ON, Canada). MH broth was
used for antimicrobial susceptibility testing, polymyxin B binding, mem-
brane permeability assays, and quantitative hopanoid analysis.
Antimicrobial sensitivity testing. The MICs of all single antibiotics
were determined by the standard microtiter broth dilution method in
accordance with the protocols outlined by the Clinical and Laboratory
Standards Institute (29). MICs of polycationic antimicrobials were deter-
mined in 96-well polypropylene plates (Corning Inc., Corning, NY). In-
teractions between fosmidomycin and colistin were evaluated by using
checkerboard broth titrations in 96-well plates. The fractional inhibitory
concentration (FIC) was calculated as the MIC of the antimicrobial in
combination with 256 g/ml fosmidomycin divided by the MIC of the
antimicrobial alone. FIC indices (FICIs) cannot be determined for Bcc
species, as they are highly resistant to fosmidomycin and aMIC cannot be
determined. Thus, definitions of synergy were based on the FICs of colis-
tin; synergy was defined as a FIC of 0.25, and additive activity was de-
fined as a MIC of0.25 and1, i.e., one-half of the typical FICI cutoffs
for synergy and addition (30). Colistin Etests were purchased from bio-
Mérieux (St. Laurent, QC,Canada) and performed in accordancewith the
manufacturer’s instructions.
Clinical data. B. multivorans clinical isolates were collected as part of
routine surveillance. Patient data, including colistin treatment informa-
tion, was collected with Research Ethics Board approval during a previous
retrospective clinical chart review of patients attending the child and adult
CF clinics in Vancouver, BC, Canada, between 1981 and 2008 (31).
Total lipid extraction. B. multivorans isolates were grown in MH
broth overnight and subcultured into 15 ml of MH with or without 256
g/ml of fosmidomycin and grown at 37°C with shaking at 200 rpm until
the early stationary phase (optical density at 600 nm [OD600] of approx-
imately 1.4). The bacteria were collected by centrifugation at 4,000 g for
10 min and washed twice with 10 ml phosphate-buffered saline (PBS).
The cells were resuspended in 10ml of PBS and then heat killed at 80°C for
30 min. The heat-killed bacteria were frozen and lyophilized until dry.
Lyophilized cells (11 to 19mg) were transferred into 20-ml glass vials and
suspended in 2 ml water–5 ml methanol–2.5 ml dichloromethane
(DCM). The suspended cells were sonicated in a bath sonicator (VWR
B2500A-DTH; 42-kHz radio frequency power, 85 W) for 1 h at room
temperature (RT), followed by the addition of 7.5 ml of DCM. The sam-
ples were vortexed and allowed to separate for 1 h before the lower DCM
layer was collected and dried at RT overnight. Samples were stored at
20°C. The yield of total lipids was 7.3% 1.2% of the dry cells.
UPLC-MS analysis. Protocols for total-lipid analysis by ultraperfor-
mance liquid chromatography-mass spectrometry (UPLC-MS) were
based on a Waters application note (32) with modifications. The total
lipids were dissolved in isopropanol-acetonitrile-water (2:1:1) at a final
concentration of 1 mg/ml. Bath sonication was used to facilitate the dis-
solution of the lipids. The samples (5 l/injection, three replicates per
sample, all in randomized order) were separated by a charged surface
hybrid (CSH) C18 column (Waters Acquity UPLC CSH C18, 2.1 by 100
mm, 1.7 m) and analyzed with a Waters LC-tandem MS (LC-MS/MS)
system (Acquity I classUPLCwith aXevoG2-S time-of-flight [TOF]mass
spectrometer). The column was maintained at 55°C and eluted with a
binary solvent system containing solvent A (acetonitrile-water, 60:40) and
solvent B (isopropanol-acetonitrile, 90:10), bothwith 10mMammonium
formate and 0.1% formic acid. The flow ratewas set at 400l/min, and the
elution program started at 40% B, increased linearly to 43% B in 2 min,
increased to 50% B in 0.1 min, increased linearly to 54% B over 9.9
min, jumped to 70% B in 0.1 min, increased linearly to 99% B over 5.9
min, decreased immediately to 40% B in 0.1 min, and was then main-
tained at the same level for 1.9 min. The column eluent was ionized by
electrospray ionization.MS and high-energy fragmented lipid (MSE) data
(interleaved low-energy and collisionally activated scans with argon as the
collision gas) were collected in either positive- or negative-ionmode with
m/z 100 to 1,500. MSE consists of both low- and high-energy scans ob-
Malott et al.
5212 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 2, 2014 by CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y
http://aac.asm
.org/
D
ow
nloaded from
 
tained simultaneously. The collision energy is changed in concert with
alternate pushes in the TOF mass spectrometer. During data analysis,
product ions can be associated with parent ions if they are coincident in
chromatographic time. Electrospray conditions were a capillary voltage of
2.0 kV, a cone voltage of 30V, a source offset of 60V, a source temperature
of 120°C, a desolvation temperature of 550°C, a cone gas flow rate of 20
liters/h, and a desolvation gas flow rate of 900 liters/h. TOFMS was done
in resolution mode, typically 32,000 m/m. The mass axis was calibrated
with sodium formate clusters. Leucine enkephalin was used as a mass
reference during acquisition. The data were collected in continuummode
and then converted to centroid mode for quantitative analysis with the
Quanlynx program (Waters Corporation, Milford, MA).
Membrane permeability to NPN. Membrane permeability in the
presence of increasing concentrations of colistin was assayed by using the
hydrophobic fluorescent probe 1-N-phenylnaphthylamine (NPN) as pre-
viously described for polymyxin B (18). The excitation and emission
wavelengths were set at 350 and 420 nm, respectively, and fluorescence
was measured with a Tecan Infinite M200 (Tecan, Durham, NC).
Polymyxin binding assay. The binding of fluorescent polymyxin to
whole bacteria was examined as previously described (18), with the fol-
lowing modifications. BODIPY FL-conjugated polymyxin B (Life Tech-
nologies) was used in place of the fluorescent dansyl derivative. BODIPY
FL-conjugated polymyxin decreases in fluorescence as it transitions from
a soluble to an aggregated or bound form. The assay was read in clear
96-well plates (Corning Inc.) with a Tecan Infinite M200 (Tecan) with an
excitation wavelength of 485 nm and an emission wavelength of 535 nm.
The data are reported as quenched fluorescence (fluorescence emitted
from the negative control minus fluorescence emitted from the bacterial
sample).
Statistical analysis. Prism v5.0 (GraphPad Software) was used to per-
form statistical analysis. An unpaired Student t test was used to determine
the difference between the means of independent samples, and multiple-
group comparisons were made by two-way analysis of variance
(ANOVA), followed by a Bonferroni posttest. In all cases, a P value of
0.05 was considered significant.
RESULTS AND DISCUSSION
Fosmidomycin potentiates polymyxin inhibition of B. multiv-
orans growth. B.multivorans is highly resistant to both fosmido-
mycin and polymyxins (5, 26). To determine if the growth of B.
multivorans can be synergistically inhibited by treatment with a
combination of colistin and fosmidomycin, initial MIC checker-
TABLE 1 Antimicrobial activities of antibiotics, alone and in
combination with fosmidomycin, against B. multivorans ATCC 17616
Class and antimicrobial
MIC (g/ml) of antimicrobial
FICAlone
With 256 g/ml
fosmidomycin
Polymyxins
Fosmidomycin 256
Colistin (polymyxin E) 256 64 0.25
Polymyxin B 256 64 0.25
Aminoglycosides
Gentamicin 64 64 1
Tobramycin 8 8 1
	-Lactam ampicillin 256 256 1
TABLE 2 Antimicrobial activities of fosmidomycin and colistin, alone
and in combination, against a panel of bacterial isolates and strains
Strain or isolate
MIC (g/ml)
FICFosmidomycin Colistin
Colistin with
256 g/ml
fosmidomycin
B. multivorans
ATCC 17616 256 256 64 0.25
26D7 256 32 32 1
RMI17 256 64 64 1
C6398 256 512 512 1
D2433 256 512 8 0.016
D2434 256 64 8 0.125
D1285 256 512 512 1
D2408 256 64 16 0.25
B. cenocepacia K56-2 256 512 512 1
P. aeruginosa
ATCC 27853
8 1 1 NAa
a NA, not applicable.
TABLE 3MIC of colistin against B. multivorans sequential, genetically
related clinical isolates
Patient and
isolate Isolation date RAPD type
Colistin MIC
(g/ml)a
A
C6398 February 1995 BM-049 512
D2434 April 2007 BM-049 64
B
D1285 September 2004 BM-044 512
D2408 March 2007 BM-044 64
C
C8298 September 1998 BM-029 512
D2156 August 2006 BM-029 512
D
C8814 October 1999 BM-055 512
D0999 January 2004 BM-055 512
E
D0400 November 2002 BM-055 512
D2420 April 2007 BM-055 512
F
C7062 April 1996 BM-020 512
C9496 January 2001 BM-020 512
G
C6396 February 1995 BM-049 512
D0913 November 2003 BM-049 512
H
C9861 September 2001 BM-032 512
D1268 August 2004 BM-032 512
I
D1407 December 2004 BM-042 512
D2324 January 2007 BM-042 512
J
C9876 October 2005 BM-055 512
D2181 September 2006 BM-055 512
a MIC determined by broth microdilution.
Fosmidomycin Potentiates the Effects of Colistin
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board titrations testing a range of fosmidomycin concentrations
(64 to 256g/ml) with a range of colistin concentrations (8 to 512
g/ml) were performed with B. multivorans isolate ATCC 17616
(data not shown). Fosmidomycin at a concentration of 256g/ml
decreased the MIC of colistin 4-fold, from 256 to 64 g/ml. The
FIC was 0.25 (Table 1), indicating synergistic inhibition of the
growth of B.multivorans 17616 by these two antimicrobial agents
in vitro.
To determine if the potentiating effect of fosmidomycin was
specific for colistin, other antimicrobial classes that perturb the
bacterialmembranewere tested in concert with fosmidomycin for
inhibition of B. multivorans growth (Table 1). The antimicrobial
activities of polymyxin B, the aminoglycosides gentamicin and
tobramycin, and the 	-lactam ampicillin were evaluated in the
presence of 256 g/ml of fosmidomycin (Table 1). The only
classes of antimicrobials that exhibited synergy with fosmidomy-
cin were the polymyxins.
Because the isoprenoid biosynthesis gene BCAL2710ispH in B.
cenocepacia and the homologue lytB in B. pseudomallei contribute
to polymyxin resistance (12, 33), we wanted to confirm that the
mechanism by which fosmidomycin potentiates the effects of
colistin is a change in hopanoids rather than other effects from the
inhibition of isoprenoid biosynthesis. Our previous work demon-
strated that the B. multivorans 17616 hopanoid biosynthesis mu-
tants 26D7 and RMI17 are specifically more susceptible to poly-
myxin B and colistin (18). The genes impacted in these mutants
are hpnJ, which encodes a putative hopanoid biosynthesis-associ-
ated radical S-adenosylmethionine protein, and hpnI, which en-
codes a putative hopanoid biosynthesis-associated glycosyltrans-
ferase; both are downstream of isoprenoids in the hopanoid
biosynthesis pathway and permit modifications of the hopanoid
backbone structure (18). Fosmidomycin treatment of these two
mutants did not change their colistin MICs (Table 2), suggesting
that fosmidomycin potentiates the susceptibility of B.multivorans
to colistin because of the impact of fosmidomycin on the biosyn-
thesis of particular hopanoids (e.g., glycosylated hopanoids).
Clinical B. multivorans isolates from CF patients with
chronic pulmonary infections have increased susceptibility to
colistin that is further potentiated by fosmidomycin. To inves-
tigate if combination therapy with fosmidomycin and inhalation
colistin would have clinical utility, we evaluated the synergistic
susceptibility of B. multivorans pulmonary isolates from CF pa-
tients. We first tested colistin susceptibility in archived sequential
clinical isolates of B. multivorans from 10 patients who attended
TABLE 4 Antimicrobial susceptibilities of early and late B. multivorans isolates from two CF patients
Class and antimicrobial
MIC (g/ml)
P. aeruginosa
ATCC 27853
B. multivorans
ATCC 17616
Patient A Patient B
Early isolate
C6398
Late isolate
D2434
Early isolate
D1285
Late isolate
D2408
Polymyxins
Colistin 1 256 512 64 512 64
Polymyxin B 1 256 512 32 512 32
Aminoglycosides
Gentamicin 1 64 256 512 512 4
Tobramycin 1 4 64 512 64 1
Macrolides
Erythromycin 64 64 64 256 64 64
Azithromycin 4 4 128 512 128 64
Cephalosporin ceftazidime 1 1 1 64 4 1
Fluoroquinolone ciprofloxacin 1 1 1 4 1 1
	-Lactam ampicillin 256 256 256 256 256 256
Tetracycline 16 4 4 8 8 8
Antiseptic chlorhexidine NDa 16 16 8 32 2
a ND, not determined.
TABLE 5 Summary of B. multivorans clinical isolates from patients A
and B
Patient and
isolate Isolation date RAPD type
Colistin MIC
(g/ml)a
A
C6398 21 February 1995 BM-049 256
C7263 04 September 1996 BM-049 256
C8610 04 May 1999 BM-049 256
C9294 15 September 2000 BM-049 256
D0004 10 January 2002 BM-049 256
D0496 10 January 2003 BM-049 256
D0745 27 June 2003 BM-049 256
D0746 27 June 2003 BM-049 256
D1375 03 November 2004 BM-049 32
D1441 18 January 2005 BM-049 256
D1607 30 May 2005 BM-049 64
D2122 28 June 2006 BM-049 256
D2356 28 February 2007 BM-049 256
D2357 28 February 2007 BM-049 256
D2433 17 April 2007 BM-049 256
D2434 17 April 2007 BM-049 64
B
D1285 23 September 2004 BM-044 256
D1446 31 January 2005 BM-044 256
D2179 15 September 2006 BM-044 256
D2408 28 March 2007 BM-044 16
a MIC determined by Etest.
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CF clinics inVancouver, BC,Canada, between 1995 and 2007. The
MICs for colistin were determined for 10 genetically related se-
quential pairs of B. multivorans isolates, as determined by random
amplified polymorphic DNA (RAPD) analysis (34), and repre-
senting early and late stages of chronic infection. For all but two of
the isolates tested, the MICs of colistin were 512 g/ml (Table
3). Notably, the late-infection isolates from patients A and B had a
colistinMIC of 64g/ml. To determine if these isolates were glob-
ally more susceptible to antimicrobials, the early and late isolates
from patients A and B were tested for susceptibility to a panel of
antimicrobials of various classes (Table 4). For the isolates from
patient A, late isolate D2434 was at least 16- and 8-fold more
susceptible to polymyxin B and colistin, respectively, and 2-fold
more susceptible to chlorhexidine, than early isolate C6398. Poly-
myxins and chlorhexidine are cationic agents that act by binding
to and disturbing the bacterial membrane. These data suggest that
the late isolate from patient A has undergone changes to its
membrane during the course of pulmonary infection that led
to increased susceptibility to these agents. Isolate D2434 was
more resistant to all of the other antimicrobials than C6398
was, except for ampicillin where no change was observed. Late
isolate D2408 from patient B was more susceptible to most of
the antimicrobials than early isolate D1285 was.
Temporal changes in the antimicrobial resistance phenotypes
of CF Bcc infections have been described, although not yet for
polymyxins (35, 36). To further understand the dynamics of colis-
tin resistance in bacteria from these twopatients, the colistinMICs
for all of the archived B. multivorans isolates from each of the
patients were determined (Table 5). After9.5 years of infection,
B. multivorans isolates with increased colistin susceptibility were
cultured from this patient. During long-term pulmonary coloni-
zation, multiple phenotypic variants of an underlying clonal bac-
terial population can emerge and become established in the pa-
tient’s airways (37). The more susceptible isolates were a
subpopulation in the lungs of patient A, as isolates with colistin
MICs of256g/ml continued to be isolated late in the infection
(Table 5). The archived collection from patient B only had four B.
multivorans isolates. These isolates were recovered over 3 years of
chronic infection. The latest isolate, D2408, was the only one with
increased sensitivity to polymyxins (Table 5).
After establishing that the MICs of colistin for chronic B.mul-
tivorans pulmonary isolates can decrease over the course of infec-
tion, we assessed if fosmidomycin could further enhance the colis-
tin susceptibility of these isolates. The early and late clinical
isolates from patients A and B were tested for fosmidomycin sus-
ceptibility alone and for antimicrobial synergy with colistin. All of
the clinical isolates had fosmidomycinMICs of256g/ml.With
the addition of 256 g/ml fosmidomycin, the MICs of colistin for
D2434 and D2408 were reduced 8- and 4-fold, respectively, over
that of colistin alone (Table 2). The FICs of 0.125 and 0.25, respec-
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FIG 1 Mass spectra of underivatized BHT-CE identified in B. multivorans. (A) Spectra taken in a low-energy channel in the positive-ion mode showing the
protonated (m/z 708.5451) and sodiated hopanoid (m/z 730.5225) molecular ions. The calculated mass and structure are shown. (B) Spectrum taken in a
high-energy channel in the positive-ion mode showing the decrease in the intensity of the protonated BHT-CE concomitant with the appearance of its
fragmented daughter ions of m/z 180.0861 and 222.0953. The fragmented structures and their calculated masses are shown.
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tively, indicate antimicrobial synergy. Isolate D2433 was obtained
from patient A on the same day as isolate D2434. This isolate was
highly resistant to colistin and fosmidomycin, but treatment of the
isolate with 256 g/ml fosmidomycin decreased the colistin MIC
for the isolate 64-fold (FIC of 0.016). This is evidence that
even isolates from chronic infections with extreme colistin resis-
tance can becomemore susceptible to colistin with the addition of
fosmidomycin.
There are no available clinical breakpoints for colistin and B.
multivorans. As a point of reference for a clinical context, the
breakpoint for P. aeruginosa is 8 g/ml (29). A strategy to fur-
ther enhance the antibacterial effect of antibiotics is to deliver the
agents directly to the site of infection by the aerosol route. Routine
application of nebulized colistin, alone or in combination with
other inhaled or parenteral antibiotics, is often used inCF patients
(38). Sputum colistin concentrations of 20g/ml can be achieved
and maintained for4 h of treatment with a well-tolerated dose
of 200 U of colistin administered by nebulizer (39). The concen-
trations of fosmidomycin used in our in vitro studies could not be
achieved in serum by using well-tolerated doses (40). Aerosolized
fosmidomycin or antimicrobials that specifically target hopanoids
may prove effective at a physiologically relevant dose.
Mechanism of fosmidomycin and colistin synergy inB.mul-
tivorans clinical isolates. To determine whether the molecular
mechanism of the synergy between fosmidomycin and colistin in
B. multivorans correlates with the abundance of particular ho-
panoids, we measured the impact of fosmidomycin on hopanoid
production and membrane permeability. As a first step in ho-
panoid quantification, the hopanoids of B.multivoranswere iden-
tified. Lipid extracts from B. multivorans clinical isolates C6398
and D2434 were analyzed by a novel LC-MS/MS approach to di-
rectly detect nonderivatized hopanoids. One-step total lipid ex-
traction was performed, and the native lipids were analyzed di-
rectly without any common derivatization such as acetylation for
hopanoids or saponification for phospholipids to minimize arti-
facts associated with these modifications that could affect lipid
quantification. The resulting MS data were then matched against
the database in the LIPID MAPS Lipidomics Gateway (http:
//www.lipidmaps.org) (41). A close hit to a specific hopanoid,
bacteriohopanetetrol cyclitol ether (BHT-CE), also known as bac-
teriohopanetetrol carbapseudopentose ether, was found in the
sample (Fig. 1A). This hopanoid has also been identified in other
Burkholderia species (23).
To confirm the identity of this hopanoid, structural informa-
tion was obtained by fragmentation of the molecular ion under
higher collisional energy to form daughter ions. Daughter ions
corresponding to breaking of the ether bond and the carbon-car-
bon bond at the hydroxyl tails were observed (Fig. 1B). A similar
fragmentation pattern of BHT-CE in its acetylated form has been
observed previously, further supporting our structural assign-
ment (42). While we looked for the presence of other common
hopanoids, such as diplopterol, adenosylhopane, bacterio-
hopanetetrol, and bacteriohopaneaminotriol, in our B. multiv-
orans samples, we could detect only a trace amount of diplopterol
(
1% of the peak intensity of BHT-CE).We therefore focused on
the quantification of BHT-CE in B. multivorans.
To determine if fosmidomycin alters the amount of BHT-CE
in the membrane of B. multivorans isolates, we performed quan-
titative LC-MS/MS on total lipid extracts in the presence or ab-
sence of 256g/ml fosmidomycin (Fig. 2). BHT-CE eluted at 4.24
min (Fig. 2B). We verified that there were no analytes coeluting
with hopanoids, ensuring that variable ion suppression effects in
FIG 2 Effect of fosmidomycin on the dominant hopanoid forms (BHT-CE) in B. multivorans clinical isolates. LC-MS base peak chromatogram of total lipids
from B. multivorans clinical isolates. Five micrograms of total lipids from each clinical isolate was separated in a hybrid C18 column and analyzed by TOF MS.
Representative chromatograms (recorded in the positive-ion mode) of three biological replicates, each containing three technical replicates, are shown. (A)
Clinical isolates C6398 and D2434 in the absence or presence of 256 g/ml of fosmidomycin. (B) Six-fold vertical expansion of the region of panel A where
BHT-CE elutes. (C) Graphic representation of the sum of the area of peak integration from the protonated and sodiated hopanoid chromatogram (panel B).
Bacteria grown without fosmidomycin (white bars) or with 256g/ml of fosmidomycin (black bars). The data are mean values of three technical replicates each
of three biological replicate samples (i.e., n 9) the standard errors of the means. Asterisks denote significant differences (P 0.05; unpaired t test).
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the electrospray process are similar among all of the data sets.
Therefore, the quantitation reported is accurate to the levels
claimed. MS signals from the protonated and sodiated hopanoid
were integrated, and the results are shown in Fig. 2C. The total
lipid extract of D2434 contained significantly more BHT-CE than
that of C6398 (P  0.05; Student’s t test). The identification of
hopanoid biosynthesis as a dynamic phenotype during the course
of infection implies that this phenotype has clinical relevance. In-
tuitively, the isolate expressing the most hopanoids would be
more resistant to membrane-disrupting agents. However, poly-
myxin resistance in Bcc bacteria is complex, with multiple means
of resistance working in concert. Although hopanoids certainly
contribute to polymyxin resistance in B.multivorans, they are not
essential (18). At any time during the course of an infection, di-
versemechanisms could contribute to the polymyxin resistance of
any isolate.
As hypothesized, the addition of fosmidomycin significantly
decreased the amounts of BHT-CE in the total lipid extracts of
isolates C6398 and D2434 by 40 and 49%, respectively (Fig. 2C).
The change in lipids due to fosmidomycin treatment translated
into antimicrobial synergy for D2434 but not C6398. To deter-
mine if fosmidomycin treatment impactsmembrane permeability
in both clinical isolates, NPN uptake assays were performed. NPN
is a hydrophobic compound that fluoresces weakly in a hydro-
philic environment, as in the periplasm of Gram-negative bacte-
ria. An increase in membrane permeability and uptake of NPN is
measured as an increase in fluorescence (43). As expected from the
antimicrobial synergy data, isolate C6398 remained highly imper-
meable in the presence of colistin and fosmidomycin (Fig. 3A).
Isolate D2434 was remarkably impermeable when treated with
colistin alone but was significantly more permeable when treated
with 256g/ml fosmidomycin at all of the concentrations of colis-
tin tested (P  0.05; ANOVA, Bonferroni posttest) (Fig. 3B).
Colistin-sensitiveP. aeruginosaATCC27853was used as a positive
control in the assay.
To determine if fosmidomycin treatment has an impact on the
binding of polymyxin, the level of antimicrobial binding was eval-
uated by using BODIPY-conjugated polymyxin B (B-PMX) (Fig.
4). Binding of the conjugated antimicrobial to the bacterial mem-
brane quenches the fluorescence (44). There was no difference in
fluorescence when whole cells of D2434 were exposed to B-PMX
in the presence or absence of 256 g/ml of fosmidomycin, sug-
gesting that under such conditions, fosmidomycin does not affect
the binding of B-PMX to the outer membrane of D2434. This
result is expected, as the increased colistin susceptibility exhibited
by the B. multivorans hopanoid biosynthesis mutants is due to
alteredmembrane permeability in the hopanoid biosynthesismu-
tants but not to an alteration of polymyxin binding capacity (18).
The data herein reveal BHT-CE production and polymyxin
resistance as heterogeneous phenotypes of Bcc bacteria that are
dynamic during the course of infection in CF patients. Our work
shows that the pharmacological suppression of membrane ho-
panoids in certain clinical B. multivorans isolates can potentiate
FIG 3 Effects of increasing concentrations of colistin on the outer membrane
permeability of B. multivorans clinical isolates from patient A. Colistin was
titrated into suspensions of whole bacteria at anOD600 of 0.5 and 10MNPN.
An increase in fluorescence corresponded to an increase in membrane perme-
ability and uptake of NPN into the hydrophobic inner and outer membranes.
Data were calculated as the fluorescence with colistin minus the fluorescence
without colistin and represent the mean values of three biological replicates
the standard errors of the means. Solid lines; medium alone, dashed lines, 256
g/ml fosmidomycin. (A) Symbols:, B.multivoransC6398;, P. aeruginosa
ATCC 27853. (B) Symbols: Œ, B. multivorans D2434; , P. aeruginosa ATCC
27853. B.multivorans D2434 was significantly more permeable to NPN in the
presence of 256 g/ml fosmidomycin at all of the concentrations of colistin
tested (P 0.05; ANOVA, Bonferroni posttest).
FIG 4 Binding of fluorescent polymyxin B to whole B. multivorans D2434.
Bacterial cells were treated with increasing concentrations of B-PMX, and
fluorescence emission at 485 nm upon excitation at 340 nm was determined.
Symbols: Œ, B.multivorans D2434; , P. aeruginosa ATCC 27853; solid lines,
medium alone; dotted line, 256 g/ml fosmidomycin. The data are the fluo-
rescence of the negative control minus the fluorescence emitted from bacteria
with conjugated polymyxin B. Shown are the mean values of three biological
replicates the standard errors of the means.
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the effects of colistin, an antimicrobial agent currently used to
treat P. aeruginosa infections in CF patients. There are few antimi-
crobial options for the therapy of Bcc infections, and eradication
of the bacteria from the lungs of people living with CF is a major
challenge (45). Further investigations are necessary to determine
if our in vitro data have the potential to translate into a clinical
application.
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